News | July 20, 2022
GSK’s Haleon begins trading in LSE
Completion of the demerger of Haleon and share consolidation of GSK
Completion of the demerger of Haleon and share consolidation of GSK
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
Glenmark’s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics, USA
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)